SUMATRIPTAN
It is a specific and selective 5-hydroxytryptamine 1-like(5HT 1-like) receptor agonist with little or no effect at a variety of other receptor types. It produces a dose-related vasoconstriction in the cerebral circulation. It does not bind to alpha adrenergic, beta adrenergic, muscarinic, dopaminergic or benzodiazepine receptors, It provides relief in both the headache & other symptoms such as nausea and photophobiaAcute treatment for migraine, severe acute pain of a cluster headache attack.
50 mg -300 mg in 24 hours or as directed by physician.
Ischaemic heart disease, hypertension.
Should not be given intravenously in patients with Ischaemic Heart Disease, hepatic impairement. Should not be given intravenously in patients with Ischaemic Heart Disease, hepatic impairement. Paediatrics: Not recommended. Pregnancy: Should not be used. Lactation: Should not be used. Elderly: Use with caution. Not recommended in age above 65 years.
Sudden wheeziness, fluttering or tightness in the chest, swelling of eyelids, face or lips, skin rash, red spots or hives.
ergotamine, lithium and MAOIs increases the risk of side effects.
Brand Name | Manufactured by |
---|---|
SUNAPRO | INTAS PHARMACEUTICALS LTD. |